PriceTargets.com logo

Myriad Genetics - MYGN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.45
  • Forecasted Upside: 56.27%
  • Number of Analysts: 16
  • Breakdown:
  • 2 Sell Ratings
  • 10 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.33 As of 12/4/2025 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for MYGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Myriad Genetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYGN

Analyst Price Target is $11.45
▲ +56.27% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Myriad Genetics in the last 3 months. The average price target is $11.45, with a high forecast of $21.00 and a low forecast of $6.00. The average price target represents a 56.27% upside from the last price of $7.33.

This chart shows the closing price for MYGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 16 investment analysts is to hold stock in Myriad Genetics. This rating has held steady since May 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 2 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 2 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 11 hold ratings
  • 2 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 2 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/17/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/11/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/11/2025Piper SandlerLower TargetOverweight ➝ Overweight$9.00 ➝ $8.50
11/5/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/5/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$6.00 ➝ $6.50
11/4/2025CowenReiterated RatingHold ➝ Hold
11/4/2025UBS GroupBoost TargetNeutral ➝ Neutral$6.00 ➝ $8.00
11/4/2025TD CowenBoost TargetHold ➝ Hold$8.00 ➝ $9.00
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
5/21/2025ScotiabankDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.00
5/15/2025Piper SandlerLower TargetOverweight ➝ Overweight$12.50 ➝ $9.00
5/8/2025Wolfe ResearchDowngradeOutperform ➝ Peer Perform
5/7/2025Craig HallumSet TargetBuy ➝ Buy$18.00
5/7/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$14.00 ➝ $8.00
5/7/2025Raymond James FinancialReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.00
5/7/2025UBS GroupLower TargetNeutral ➝ Neutral$16.00 ➝ $7.00
5/7/2025Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$22.00 ➝ $6.00
4/17/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$18.00 ➝ $14.00
4/9/2025GuggenheimDowngradeBuy ➝ Neutral
4/1/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$24.00 ➝ $20.00
3/12/2025Piper SandlerUpgradeNeutral ➝ Overweight$11.50 ➝ $12.50
3/4/2025Piper SandlerLower TargetNeutral ➝ Neutral$14.00 ➝ $11.50
3/3/2025Bank of AmericaLower TargetUnderperform ➝ Underperform$13.00 ➝ $11.00
2/25/2025Raymond James FinancialReiterated RatingOutperform ➝ Outperform$27.00 ➝ $19.00
2/25/2025UBS GroupLower TargetNeutral ➝ Neutral$18.00 ➝ $16.00
2/12/2025Craig HallumInitiated CoverageBuy$29.00
1/30/2025Piper SandlerLower TargetNeutral ➝ Neutral$24.00 ➝ $14.00
1/28/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$29.00 ➝ $18.00
1/16/2025StephensReiterated RatingEqual Weight ➝ Equal Weight$20.00 ➝ $20.00
12/13/2024Bank of AmericaLower TargetUnderperform ➝ Underperform$15.00 ➝ $13.00
12/10/2024UBS GroupInitiated CoverageNeutral$18.00
12/9/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
12/9/2024Leerink PartnersDowngradeOutperform ➝ Market Perform$30.00 ➝ $21.00
11/18/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$32.00 ➝ $21.00
11/11/2024Piper SandlerLower TargetNeutral ➝ Neutral$30.00 ➝ $24.00
9/19/2024Morgan StanleyInitiated CoverageEqual Weight$32.00
8/27/2024Wells Fargo & CompanyInitiated CoverageOverweight$35.00
8/13/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$29.00 ➝ $34.00
8/13/2024Piper SandlerBoost TargetNeutral ➝ Neutral$28.00 ➝ $30.00
8/7/2024TD CowenBoost TargetHold ➝ Hold$28.00 ➝ $30.00
8/7/2024JPMorgan Chase & Co.Boost TargetUnderweight ➝ Underweight$17.00 ➝ $20.00
6/27/2024ScotiabankInitiated CoverageSector Outperform$29.00
6/3/2024Jefferies Financial GroupReiterated RatingHold ➝ Underperform$25.00 ➝ $20.00
5/13/2024Piper SandlerBoost TargetNeutral ➝ Neutral$23.00 ➝ $28.00
5/8/2024Leerink PartnrsUpgradeMarket Perform ➝ Outperform
5/8/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$25.00 ➝ $35.00
1/29/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$28.00 ➝ $31.00
12/21/2023Piper SandlerInitiated CoverageNeutral$23.00
12/19/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$20.00
12/14/2023GuggenheimInitiated CoverageBuy$23.00
12/13/2023Wolfe ResearchInitiated CoverageOutperform$28.00
11/7/2023JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$17.00 ➝ $14.00
8/7/2023JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$18.00 ➝ $17.00
7/21/2023The Goldman Sachs GroupBoost TargetBuy$25.00 ➝ $28.00
5/23/2023The Goldman Sachs GroupUpgradeSell ➝ Buy$18.00 ➝ $25.00
3/6/2023StephensBoost TargetEqual Weight$17.00 ➝ $24.00
3/3/2023Raymond James FinancialBoost TargetOutperform$25.00 ➝ $27.00
1/18/2023Raymond James FinancialUpgradeMarket Perform ➝ Outperform$25.00
11/2/2022Leerink PartnersLower TargetMarket Perform$27.00 ➝ $25.00
10/5/2022StephensInitiated CoverageEqual Weight$22.00
8/9/2022CowenBoost Target$32.00
8/5/2022Leerink PartnersBoost TargetMarket Perform$26.00 ➝ $30.00
7/19/2022CowenSet Target$25.00
4/19/2022The Goldman Sachs GroupLower TargetSell$26.00 ➝ $23.00
11/3/2021Leerink PartnersLower TargetMarket Perform$36.00 ➝ $35.00
6/15/2021Raymond James FinancialInitiated CoverageMarket Perform
6/3/2021The Goldman Sachs GroupInitiated CoverageSell$25.00
2/24/2021Leerink PartnersBoost TargetMarket Perform$20.00 ➝ $33.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 16 very positive mentions
  • 30 positive mentions
  • 8 negative mentions
  • 4 very negative mentions
Mentions as of
5/9/2025
  • 10 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
Mentions as of
6/8/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/7/2025
  • 15 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
9/6/2025
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 8 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
11/5/2025
  • 8 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 8 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Myriad Genetics logo
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $7.33
Low: $7.15
High: $7.38

50 Day Range

MA: $7.43
Low: $6.30
High: $8.18

52 Week Range

Now: $7.33
Low: $3.76
High: $16.63

Volume

695,097 shs

Average Volume

1,165,076 shs

Market Capitalization

$683.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Myriad Genetics?

The following sell-side analysts have issued reports on Myriad Genetics in the last year: Bank of America Corporation, Cowen Inc, Craig Hallum, Guggenheim, Leerink Partners, Leerink Partnrs, Piper Sandler, Raymond James Financial, Inc., Scotiabank, Stephens, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for MYGN.

What is the current price target for Myriad Genetics?

0 Wall Street analysts have set twelve-month price targets for Myriad Genetics in the last year. Their average twelve-month price target is $11.45, suggesting a possible upside of 56.3%. Leerink Partners has the highest price target set, predicting MYGN will reach $21.00 in the next twelve months. Scotiabank has the lowest price target set, forecasting a price of $6.00 for Myriad Genetics in the next year.
View the latest price targets for MYGN.

What is the current consensus analyst rating for Myriad Genetics?

Myriad Genetics currently has 2 sell ratings, 10 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYGN, but not buy more shares or sell existing shares.
View the latest ratings for MYGN.

What other companies compete with Myriad Genetics?

Other companies that are similar to Myriad Genetics include Zenas BioPharma, Celldex Therapeutics, MannKind, Innoviva and BioCryst Pharmaceuticals. Learn More about companies similar to Myriad Genetics.

How do I contact Myriad Genetics' investor relations team?

Myriad Genetics' physical mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company's listed phone number is (801) 584-3600 and its investor relations email address is [email protected]. The official website for Myriad Genetics is www.myriad.com. Learn More about contacing Myriad Genetics investor relations.